BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Case JB, Rothlauf PW, Chen RE, Kafai NM, Fox JM, Smith BK, Shrihari S, McCune BT, Harvey IB, Keeler SP, Bloyet LM, Zhao H, Ma M, Adams LJ, Winkler ES, Holtzman MJ, Fremont DH, Whelan SPJ, Diamond MS. Replication-Competent Vesicular Stomatitis Virus Vaccine Vector Protects against SARS-CoV-2-Mediated Pathogenesis in Mice. Cell Host Microbe 2020;28:465-474.e4. [PMID: 32798445 DOI: 10.1016/j.chom.2020.07.018] [Cited by in Crossref: 62] [Cited by in F6Publishing: 101] [Article Influence: 31.0] [Reference Citation Analysis]
Number Citing Articles
1 Taddeo A, Veiga IB, Devisme C, Boss R, Plattet P, Weigang S, Kochs G, Thiel V, Benarafa C, Zimmer G. Optimized intramuscular immunization with VSV-vectored spike protein triggers a superior immune response to SARS-CoV-2. npj Vaccines 2022;7. [DOI: 10.1038/s41541-022-00508-7] [Reference Citation Analysis]
2 Ao Z, Ouyang MJ, Olukitibi TA, Warner B, Vendramelli R, Truong T, Meilleur C, Zhang M, Kung S, Fowke KR, Kobasa D, Yao X. A Recombinant VSV-Based Bivalent Vaccine Effectively Protects against Both SARS-CoV-2 and Influenza A Virus Infection. J Virol 2022;:e0133722. [PMID: 36069551 DOI: 10.1128/jvi.01337-22] [Reference Citation Analysis]
3 Mei S, Fan Z, Liu X, Zhao F, Huang Y, Wei L, Hu Y, Xie Y, Wang L, Ai B, Liang C, Xu F, Guo F. Immunogenicity of a vaccinia virus-based severe acute respiratory syndrome coronavirus 2 vaccine candidate. Front Immunol 2022;13:911164. [DOI: 10.3389/fimmu.2022.911164] [Reference Citation Analysis]
4 Liu K, Han Y, Wu G, Huang KA, Huang P. Overview of Neutralization Assays and International Standard for Detecting SARS-CoV-2 Neutralizing Antibody. Viruses 2022;14:1560. [DOI: 10.3390/v14071560] [Reference Citation Analysis]
5 Zhang Y, Nagalo BM. Immunovirotherapy Based on Recombinant Vesicular Stomatitis Virus: Where Are We? Front Immunol 2022;13:898631. [DOI: 10.3389/fimmu.2022.898631] [Reference Citation Analysis]
6 Labriola JM, Miersch S, Chen G, Chen C, Pavlenco A, Saberianfar R, Caccuri F, Zani A, Sharma N, Feng A, Leung DW, Caruso A, Novelli G, Amarasinghe GK, Sidhu SS. Peptide-Antibody Fusions Engineered by Phage Display Exhibit an Ultrapotent and Broad Neutralization of SARS-CoV-2 Variants. ACS Chem Biol 2022. [PMID: 35731947 DOI: 10.1021/acschembio.2c00411] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Lin J, Tien C, Kuo Y, Lin E, Tsai W, Chen M, Tsai P, Su Y, Pathak N, Yang J, Yu C, Chuang Z, Wu H, Tsai W, Dai S, Liao H, Chai KM, Su Y, Chuang T, Liu S, Chen H, Dou H, Chen F, Chen C, Liao C, Yu G. Furin and TMPRSS2 Resistant Spike Induces Robust Humoral and Cellular Immunity Against SARS-CoV-2 Lethal Infection. Front Immunol 2022;13:872047. [DOI: 10.3389/fimmu.2022.872047] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Lin Q, Lu C, Hong Y, Li R, Chen J, Chen W, Chen J. Animal models for studying coronavirus infections and developing antiviral agents and vaccines. Antiviral Research 2022. [DOI: 10.1016/j.antiviral.2022.105345] [Reference Citation Analysis]
9 Ying B, Scheaffer SM, Whitener B, Liang CY, Dmytrenko O, Mackin S, Wu K, Lee D, Avena LE, Chong Z, Case JB, Ma L, Kim TTM, Sein CE, Woods A, Berrueta DM, Chang GY, Stewart-Jones G, Renzi I, Lai YT, Malinowski A, Carfi A, Elbashir SM, Edwards DK, Thackray LB, Diamond MS. Boosting with variant-matched or historical mRNA vaccines protects against Omicron infection in mice. Cell 2022;185:1572-1587.e11. [PMID: 35452622 DOI: 10.1016/j.cell.2022.03.037] [Cited by in Crossref: 3] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
10 Brumeanu TD, Vir P, Karim AF, Kar S, Benetiene D, Lok M, Greenhouse J, Putmon-Taylor T, Kitajewski C, Chung KK, Pratt KP, Casares SA. Human-Immune-System (HIS) humanized mouse model (DRAGA: HLA-A2.HLA-DR4.Rag1KO.IL-2RγcKO.NOD) for COVID-19. Hum Vaccin Immunother 2022;:1-16. [PMID: 35348437 DOI: 10.1080/21645515.2022.2048622] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Al-awwal N, Dweik F, Mahdi S, El-dweik M, Anderson SH. A Review of SARS-CoV-2 Disease (COVID-19): Pandemic in Our Time. Pathogens 2022;11:368. [DOI: 10.3390/pathogens11030368] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
12 Walls AC, Sprouse KR, Bowen JE, Joshi A, Franko N, Navarro MJ, Stewart C, Cameroni E, McCallum M, Goecker EA, Degli-Angeli EJ, Logue J, Greninger A, Corti D, Chu HY, Veesler D. SARS-CoV-2 breakthrough infections elicit potent, broad, and durable neutralizing antibody responses. Cell 2022;185:872-880.e3. [PMID: 35123650 DOI: 10.1016/j.cell.2022.01.011] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 30.0] [Reference Citation Analysis]
13 Kim C, Kim JD, Seo SU. Nanoparticle and virus-like particle vaccine approaches against SARS-CoV-2. J Microbiol 2022;60:335-46. [PMID: 35089583 DOI: 10.1007/s12275-022-1608-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
14 Lee MH, Kim BJ. COVID-19 vaccine development based on recombinant viral and bacterial vector systems: combinatorial effect of adaptive and trained immunity. J Microbiol 2022;60:321-34. [PMID: 35157221 DOI: 10.1007/s12275-022-1621-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
15 Lundstrom K. Self-replicating vehicles based on negative strand RNA viruses. Cancer Gene Ther 2022. [PMID: 35169298 DOI: 10.1038/s41417-022-00436-7] [Reference Citation Analysis]
16 O'Donnell KL, Clancy CS, Griffin AJ, Shifflett K, Gourdine T, Thomas T, Long CM, Furuyama W, Marzi A. Optimization of Single-Dose VSV-Based COVID-19 Vaccination in Hamsters. Front Immunol 2021;12:788235. [PMID: 35069564 DOI: 10.3389/fimmu.2021.788235] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
17 Pecetta S, Kratochvil S, Kato Y, Vadivelu K, Rappuoli R. Immunology and Technology of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines. Pharmacol Rev 2022;74:313-39. [PMID: 35101964 DOI: 10.1124/pharmrev.120.000285] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Ding LS, Zhang Y, Wen D, Ma J, Yuan H, Li H, Duo S, Yuan F, Zhang YE, Zheng A. Growth, Antigenicity, and Immunogenicity of SARS-CoV-2 Spike Variants Revealed by a Live rVSV-SARS-CoV-2 Virus. Front Med (Lausanne) 2021;8:793437. [PMID: 35071273 DOI: 10.3389/fmed.2021.793437] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Li N, Chen XL, Li Q, Zhang ZR, Deng CL, Zhang B, Li XD, Ye HQ. A new screening system for entry inhibitors based on cell-to-cell transmitted syncytia formation mediated by self-propagating hybrid VEEV-SARS-CoV-2 replicon. Emerg Microbes Infect 2022;:1-28. [PMID: 35034586 DOI: 10.1080/22221751.2022.2030198] [Reference Citation Analysis]
20 Salazar-garcía M, Acosta-contreras S, Rodríguez-martínez G, Cruz-rangel A, Flores-alanis A, Patiño-lópez G, Luna-pineda VM. Pseudotyped Vesicular Stomatitis Virus-Severe Acute Respiratory Syndrome-Coronavirus-2 Spike for the Study of Variants, Vaccines, and Therapeutics Against Coronavirus Disease 2019. Front Microbiol 2022;12:817200. [DOI: 10.3389/fmicb.2021.817200] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
21 Furuyama W, Shifflett K, Pinski AN, Griffin AJ, Feldmann F, Okumura A, Gourdine T, Jankeel A, Lovaglio J, Hanley PW, Thomas T, Clancy CS, Messaoudi I, O'Donnell KL, Marzi A. Rapid Protection from COVID-19 in Nonhuman Primates Vaccinated Intramuscularly but Not Intranasally with a Single Dose of a Vesicular Stomatitis Virus-Based Vaccine. mBio 2022;:e0337921. [PMID: 35012339 DOI: 10.1128/mbio.03379-21] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
22 Bankwitz D, Krey T, Pietschmann T. [Development approaches for vaccines against hepatitis C virus infections]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2022. [PMID: 35015104 DOI: 10.1007/s00103-021-03477-9] [Reference Citation Analysis]
23 Peng KW, Carey T, Lech P, Vandergaast R, Muñoz-Alía MÁ, Packiriswamy N, Gnanadurai C, Krotova K, Tesfay M, Ziegler C, Haselton M, Sevola K, Lathrum C, Reiter S, Narjari R, Balakrishnan B, Suksanpaisan L, Sakuma T, Recker J, Zhang L, Waniger S, Russell L, Petro CD, Kyratsous CA, Baum A, Janecek JL, Lee RM, Ramachandran S, Graham ML, Russell SJ. Boosting of SARS-CoV-2 immunity in nonhuman primates using an oral rhabdoviral vaccine. Vaccine 2022:S0264-410X(21)01671-6. [PMID: 35282925 DOI: 10.1016/j.vaccine.2021.12.063] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
24 Shan D, Tang X, Liu R, Pan D, Wang X, Ge J, Wen Z, Bu Z. Immunogenicity of a Recombinant VSV-Vectored SARS-CoV Vaccine Induced Robust Immunity in Rhesus Monkeys after Single-Dose Immunization. Virologica Sinica 2022. [DOI: 10.1016/j.virs.2022.01.002] [Reference Citation Analysis]
25 Ohtsuka J, Imai M, Fukumura M, Maeda M, Eguchi A, Ono R, Maemura T, Ito M, Yamayoshi S, Kataoka Y, Kawaoka Y, Nosaka T. Non-propagative human parainfluenza virus type 2 nasal vaccine robustly protects the upper and lower airways against SARS-CoV-2. iScience 2021;24:103379. [PMID: 34805782 DOI: 10.1016/j.isci.2021.103379] [Reference Citation Analysis]
26 Kim GN, Choi JA, Wu K, Saeedian N, Yang E, Park H, Woo SJ, Lim G, Kim SG, Eo SK, Jeong HW, Kim T, Chang JH, Seo SH, Kim NH, Choi E, Choo S, Lee S, Winterborn A, Li Y, Parham K, Donovan JM, Fenton B, Dikeakos JD, Dekaban GA, Haeryfar SMM, Troyer RM, Arts EJ, Barr SD, Song M, Kang CY. A vesicular stomatitis virus-based prime-boost vaccination strategy induces potent and protective neutralizing antibodies against SARS-CoV-2. PLoS Pathog 2021;17:e1010092. [PMID: 34914812 DOI: 10.1371/journal.ppat.1010092] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
27 Dangi T, Palacio N, Sanchez S, Park M, Class J, Visvabharathy L, Ciucci T, Koralnik IJ, Richner JM, Penaloza-MacMaster P. Cross-protective immunity following coronavirus vaccination and coronavirus infection. J Clin Invest 2021;131:e151969. [PMID: 34623973 DOI: 10.1172/JCI151969] [Cited by in Crossref: 7] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
28 Walls AC, Sprouse KR, Joshi A, Bowen JE, Franko N, Navarro MJ, Stewart C, McCallum M, Goecker EA, Degli-Angeli EJ, Logue J, Greninger A, Chu H, Veesler D. Delta breakthrough infections elicit potent, broad and durable neutralizing antibody responses. bioRxiv 2021:2021. [PMID: 34931192 DOI: 10.1101/2021.12.08.471707] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
29 Cao H, Mai J, Zhou Z, Li Z, Duan R, Watt J, Chen Z, Bandara RA, Li M, Ahn SK, Poon B, Christie-Holmes N, Gray-Owen SD, Banerjee A, Mossman K, Kozak R, Mubareka S, Rini JM, Hu J, Liu J. Intranasal HD-Ad vaccine protects the upper and lower respiratory tracts of hACE2 mice against SARS-CoV-2. Cell Biosci 2021;11:202. [PMID: 34879865 DOI: 10.1186/s13578-021-00723-0] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
30 Cordeiro AS, Patil-Sen Y, Shivkumar M, Patel R, Khedr A, Elsawy MA. Nanovaccine Delivery Approaches and Advanced Delivery Systems for the Prevention of Viral Infections: From Development to Clinical Application. Pharmaceutics 2021;13:2091. [PMID: 34959372 DOI: 10.3390/pharmaceutics13122091] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
31 Zhong C, Xia H, Adam A, Wang B, Hajnik RL, Liang Y, Rafael GH, Zou J, Wang X, Sun J, Soong L, Barrett ADT, Weaver SC, Shi PY, Wang T, Hu H. Mucosal vaccination induces protection against SARS-CoV-2 in the absence of detectable neutralizing antibodies. NPJ Vaccines 2021;6:139. [PMID: 34845215 DOI: 10.1038/s41541-021-00405-5] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
32 Makovitzki A, Lerer E, Kafri Y, Adar Y, Cherry L, Lupu E, Monash A, Levy R, Israeli O, Dor E, Epstein E, Levin L, Toister E, Hefetz I, Hazan O, Simon I, Tal A, Girshengorn M, Tzadok H, Rosen O, Oren Z. Evaluation of a downstream process for the recovery and concentration of a Cell-Culture-Derived rVSV-Spike COVID-19 vaccine candidate. Vaccine 2021;39:7044-51. [PMID: 34756612 DOI: 10.1016/j.vaccine.2021.10.045] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
33 Song J, Chow RD, Pena-Hernandez M, Zhang L, Loeb SA, So EY, Liang OD, Wilen CB, Lee S. LRRC15 is an inhibitory receptor blocking SARS-CoV-2 spike-mediated entry in trans. bioRxiv 2021:2021. [PMID: 34845449 DOI: 10.1101/2021.11.23.469714] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
34 Bohan D, Van Ert H, Ruggio N, Rogers KJ, Badreddine M, Aguilar Briseño JA, Elliff JM, Rojas Chavez RA, Gao B, Stokowy T, Christakou E, Kursula P, Micklem D, Gausdal G, Haim H, Minna J, Lorens JB, Maury W. Phosphatidylserine receptors enhance SARS-CoV-2 infection. PLoS Pathog 2021;17:e1009743. [PMID: 34797899 DOI: 10.1371/journal.ppat.1009743] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
35 Kim N, Yokobayashi Y. Novel RNA Viral Vectors for Chemically Regulated Gene Expression in Embryonic Stem Cells. ACS Synth Biol 2021;10:2959-67. [PMID: 34676762 DOI: 10.1021/acssynbio.1c00214] [Reference Citation Analysis]
36 Li H, Zhang Y, Li D, Deng YQ, Xu H, Zhao C, Liu J, Wen D, Zhao J, Li Y, Wu Y, Liu S, Liu J, Hao J, Yuan F, Duo S, Qin CF, Zheng A. Enhanced protective immunity against SARS-CoV-2 elicited by a VSV vector expressing a chimeric spike protein. Signal Transduct Target Ther 2021;6:389. [PMID: 34759261 DOI: 10.1038/s41392-021-00797-9] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
37 Pishesha N, Harmand TJ, Rothlauf PW, Praest P, Alexander RK, van den Doel R, Liebeskind MJ, Vakaki MA, McCaul N, Wijne C, Verhaar E, Pinney W 3rd, Heston H, Bloyet LM, Pontelli MC, Ilagan MXG, Jan Lebbink R, Buchser WJ, Wiertz EJHJ, Whelan SPJ, Ploegh HL. A class II MHC-targeted vaccine elicits immunity against SARS-CoV-2 and its variants. Proc Natl Acad Sci U S A 2021;118:e2116147118. [PMID: 34654739 DOI: 10.1073/pnas.2116147118] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
38 Lundstrom K. Self-Replicating RNA Viruses for Vaccine Development against Infectious Diseases and Cancer. Vaccines (Basel) 2021;9:1187. [PMID: 34696295 DOI: 10.3390/vaccines9101187] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
39 Cimolai N. Passive Immunity Should and Will Work for COVID-19 for Some Patients. Clin Hematol Int 2021;3:47-68. [PMID: 34595467 DOI: 10.2991/chi.k.210328.001] [Reference Citation Analysis]
40 Daian E Silva DSO, da Fonseca FG. The Rise of Vectored Vaccines: A Legacy of the COVID-19 Global Crisis. Vaccines (Basel) 2021;9:1101. [PMID: 34696209 DOI: 10.3390/vaccines9101101] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
41 Xu K, Dai L, Gao GF. Humoral and cellular immunity and the safety of COVID-19 vaccines: a summary of data published by 21 May 2021. Int Immunol 2021;33:529-40. [PMID: 34491327 DOI: 10.1093/intimm/dxab061] [Cited by in F6Publishing: 11] [Reference Citation Analysis]
42 Tao K, Tzou PL, Nouhin J, Gupta RK, de Oliveira T, Kosakovsky Pond SL, Fera D, Shafer RW. The biological and clinical significance of emerging SARS-CoV-2 variants. Nat Rev Genet 2021. [PMID: 34535792 DOI: 10.1038/s41576-021-00408-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 206] [Article Influence: 8.0] [Reference Citation Analysis]
43 Zabaleta N, Dai W, Bhatt U, Hérate C, Maisonnasse P, Chichester JA, Sanmiguel J, Estelien R, Michalson KT, Diop C, Maciorowski D, Dereuddre-Bosquet N, Cavarelli M, Gallouët AS, Naninck T, Kahlaoui N, Lemaitre J, Qi W, Hudspeth E, Cucalon A, Dyer CD, Pampena MB, Knox JJ, LaRocque RC, Charles RC, Li D, Kim M, Sheridan A, Storm N, Johnson RI, Feldman J, Hauser BM, Contreras V, Marlin R, Tsong Fang RH, Chapon C, van der Werf S, Zinn E, Ryan A, Kobayashi DT, Chauhan R, McGlynn M, Ryan ET, Schmidt AG, Price B, Honko A, Griffiths A, Yaghmour S, Hodge R, Betts MR, Freeman MW, Wilson JM, Le Grand R, Vandenberghe LH. An AAV-based, room-temperature-stable, single-dose COVID-19 vaccine provides durable immunogenicity and protection in non-human primates. Cell Host Microbe 2021;29:1437-1453.e8. [PMID: 34428428 DOI: 10.1016/j.chom.2021.08.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
44 Liu G, Cao W, Salawudeen A, Zhu W, Emeterio K, Safronetz D, Banadyga L. Vesicular Stomatitis Virus: From Agricultural Pathogen to Vaccine Vector. Pathogens 2021;10:1092. [PMID: 34578125 DOI: 10.3390/pathogens10091092] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
45 Stubbs SH, Cornejo Pontelli M, Mishra N, Zhou C, de Paula Souza J, Mendes Viana RM, Lipkin WI, Knipe DM, Arruda E, Whelan SPJ. Vesicular Stomatitis Virus Chimeras Expressing the Oropouche Virus Glycoproteins Elicit Protective Immune Responses in Mice. mBio 2021;12:e0046321. [PMID: 34340542 DOI: 10.1128/mBio.00463-21] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
46 Ikegame S, Siddiquey MNA, Hung CT, Haas G, Brambilla L, Oguntuyo KY, Kowdle S, Chiu HP, Stevens CS, Vilardo AE, Edelstein A, Perandones C, Kamil JP, Lee B. Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants. Nat Commun 2021;12:4598. [PMID: 34312390 DOI: 10.1038/s41467-021-24909-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 35] [Article Influence: 5.0] [Reference Citation Analysis]
47 Malherbe DC, Kurup D, Wirblich C, Ronk AJ, Mire C, Kuzmina N, Shaik N, Periasamy S, Hyde MA, Williams JM, Shi PY, Schnell MJ, Bukreyev A. A single dose of replication-competent VSV-vectored vaccine expressing SARS-CoV-2 S1 protects against virus replication in a hamster model of severe COVID-19. NPJ Vaccines 2021;6:91. [PMID: 34294728 DOI: 10.1038/s41541-021-00352-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
48 Tortorici MA, Czudnochowski N, Starr TN, Marzi R, Walls AC, Zatta F, Bowen JE, Jaconi S, Di Iulio J, Wang Z, De Marco A, Zepeda SK, Pinto D, Liu Z, Beltramello M, Bartha I, Housley MP, Lempp FA, Rosen LE, Dellota E Jr, Kaiser H, Montiel-Ruiz M, Zhou J, Addetia A, Guarino B, Culap K, Sprugasci N, Saliba C, Vetti E, Giacchetto-Sasselli I, Fregni CS, Abdelnabi R, Foo SC, Havenar-Daughton C, Schmid MA, Benigni F, Cameroni E, Neyts J, Telenti A, Virgin HW, Whelan SPJ, Snell G, Bloom JD, Corti D, Veesler D, Pizzuto MS. Broad sarbecovirus neutralization by a human monoclonal antibody. Nature 2021;597:103-8. [PMID: 34280951 DOI: 10.1038/s41586-021-03817-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 73] [Article Influence: 7.0] [Reference Citation Analysis]
49 Fenwick C, Turelli P, Pellaton C, Farina A, Campos J, Raclot C, Pojer F, Cagno V, Nusslé SG, D'Acremont V, Fehr J, Puhan M, Pantaleo G, Trono D. A high-throughput cell- and virus-free assay shows reduced neutralization of SARS-CoV-2 variants by COVID-19 convalescent plasma. Sci Transl Med 2021;13:eabi8452. [PMID: 34257144 DOI: 10.1126/scitranslmed.abi8452] [Cited by in Crossref: 1] [Cited by in F6Publishing: 22] [Article Influence: 1.0] [Reference Citation Analysis]
50 Raman R, Patel KJ, Ranjan K. COVID-19: Unmasking Emerging SARS-CoV-2 Variants, Vaccines and Therapeutic Strategies. Biomolecules 2021;11:993. [PMID: 34356617 DOI: 10.3390/biom11070993] [Cited by in Crossref: 1] [Cited by in F6Publishing: 48] [Article Influence: 1.0] [Reference Citation Analysis]
51 Jbeli R, Jelassi A. Current vaccine technology with an emphasis on recombinant measles virus as a new perspective for vaccination against SARS-CoV-2. EuroMediterr J Environ Integr 2021;6:61. [PMID: 34250222 DOI: 10.1007/s41207-021-00263-6] [Reference Citation Analysis]
52 McCallum M, Bassi J, De Marco A, Chen A, Walls AC, Di Iulio J, Tortorici MA, Navarro MJ, Silacci-Fregni C, Saliba C, Sprouse KR, Agostini M, Pinto D, Culap K, Bianchi S, Jaconi S, Cameroni E, Bowen JE, Tilles SW, Pizzuto MS, Guastalla SB, Bona G, Pellanda AF, Garzoni C, Van Voorhis WC, Rosen LE, Snell G, Telenti A, Virgin HW, Piccoli L, Corti D, Veesler D. SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern. Science 2021;373:648-54. [PMID: 34210893 DOI: 10.1126/science.abi7994] [Cited by in Crossref: 16] [Cited by in F6Publishing: 172] [Article Influence: 16.0] [Reference Citation Analysis]
53 Bohan D, Ert HV, Ruggio N, Rogers KJ, Badreddine M, Aguilar Briseño JA, Rojas Chavez RA, Gao B, Stokowy T, Christakou E, Micklem D, Gausdal G, Haim H, Minna J, Lorens JB, Maury W. Phosphatidylserine Receptors Enhance SARS-CoV-2 Infection: AXL as a Therapeutic Target for COVID-19. bioRxiv 2021:2021. [PMID: 34159331 DOI: 10.1101/2021.06.15.448419] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
54 Fischer A. SARS-CoV-2 vaccines, where do we stand? C R Biol 2021;344:43-55. [PMID: 34213848 DOI: 10.5802/crbiol.35] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
55 Lu Y, Wang J, Li Q, Hu H, Lu J, Chen Z. Advances in Neutralization Assays for SARS‐CoV‐2. Scand J Immunol 2021;94. [DOI: 10.1111/sji.13088] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
56 Darwish RM. COVID-19 immunity and vaccines: what a pharmacist needs to know. Asian Biomedicine 2021;15:51-67. [DOI: 10.2478/abm-2021-0008] [Reference Citation Analysis]
57 Ikegame S, Siddiquey MNA, Hung CT, Haas G, Brambilla L, Oguntuyo KY, Kowdle S, Vilardo AE, Edelstein A, Perandones C, Kamil JP, Lee B. Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants. medRxiv 2021:2021. [PMID: 33821288 DOI: 10.1101/2021.03.31.21254660] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
58 Elia U, Rotem S, Bar-Haim E, Ramishetti S, Naidu GS, Gur D, Aftalion M, Israeli M, Bercovich-Kinori A, Alcalay R, Makdasi E, Chitlaru T, Rosenfeld R, Israely T, Melamed S, Abutbul Ionita I, Danino D, Peer D, Cohen O. Lipid Nanoparticle RBD-hFc mRNA Vaccine Protects hACE2 Transgenic Mice against a Lethal SARS-CoV-2 Infection. Nano Lett 2021;21:4774-9. [PMID: 34032435 DOI: 10.1021/acs.nanolett.1c01284] [Cited by in Crossref: 1] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
59 Dispinseri S, Secchi M, Pirillo MF, Tolazzi M, Borghi M, Brigatti C, De Angelis ML, Baratella M, Bazzigaluppi E, Venturi G, Sironi F, Canitano A, Marzinotto I, Tresoldi C, Ciceri F, Piemonti L, Negri D, Cara A, Lampasona V, Scarlatti G. Neutralizing antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for survival. Nat Commun 2021;12:2670. [PMID: 33976165 DOI: 10.1038/s41467-021-22958-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 132] [Article Influence: 19.0] [Reference Citation Analysis]
60 Baldo A, Leunda A, Willemarck N, Pauwels K. Environmental Risk Assessment of Recombinant Viral Vector Vaccines against SARS-Cov-2. Vaccines (Basel) 2021;9:453. [PMID: 34063733 DOI: 10.3390/vaccines9050453] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
61 Bisgin A, Sanlioglu AD, Eksi YE, Griffith TS, Sanlioglu S. Current Update on Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Development with a Special Emphasis on Gene Therapy Viral Vector Design and Construction for Vaccination. Hum Gene Ther 2021;32:541-62. [PMID: 33858231 DOI: 10.1089/hum.2021.052] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
62 Bortz RH 3rd, Florez C, Laudermilch E, Wirchnianski AS, Lasso G, Malonis RJ, Georgiev GI, Vergnolle O, Herrera NG, Morano NC, Campbell ST, Orner EP, Mengotto A, Dieterle ME, Fels JM, Haslwanter D, Jangra RK, Celikgil A, Kimmel D, Lee JH, Mariano MC, Nakouzi A, Quiroz J, Rivera J, Szymczak WA, Tong K, Barnhill J, Forsell MNE, Ahlm C, Stein DT, Pirofski LA, Goldstein DY, Garforth SJ, Almo SC, Daily JP, Prystowsky MB, Faix JD, Fox AS, Weiss LM, Lai JR, Chandran K. Single-Dilution COVID-19 Antibody Test with Qualitative and Quantitative Readouts. mSphere 2021;6:e00224-21. [PMID: 33883259 DOI: 10.1128/mSphere.00224-21] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
63 Chen M, Zhang XE. Construction and applications of SARS-CoV-2 pseudoviruses: a mini review. Int J Biol Sci 2021;17:1574-80. [PMID: 33907521 DOI: 10.7150/ijbs.59184] [Cited by in Crossref: 2] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
64 Tortorici MA, Czudnochowski N, Starr TN, Marzi R, Walls AC, Zatta F, Bowen JE, Jaconi S, di Iulio J, Wang Z, De Marco A, Zepeda SK, Pinto D, Liu Z, Beltramello M, Bartha I, Housley MP, Lempp FA, Rosen LE, Dellota E Jr, Kaiser H, Montiel-Ruiz M, Zhou J, Addetia A, Guarino B, Culap K, Sprugasci N, Saliba C, Vetti E, Giacchetto-Sasselli I, Silacci Fregni C, Abdelnabi R, Caroline Foo SY, Havenar-Daughton C, Schmid MA, Benigni F, Cameroni E, Neyts J, Telenti A, Snell G, Virgin HW, Whelan SPJ, Bloom JD, Corti D, Veesler D, Pizzuto MS. Structural basis for broad sarbecovirus neutralization by a human monoclonal antibody. bioRxiv 2021:2021. [PMID: 33851169 DOI: 10.1101/2021.04.07.438818] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 11.0] [Reference Citation Analysis]
65 Ikegame S, Siddiquey MNA, Hung CT, Haas G, Brambilla L, Oguntuyo KY, Kowdle S, Vilardo AE, Edelstein A, Perandones C, Kamil JP, Lee B. Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants. Res Sq 2021:rs. [PMID: 33851150 DOI: 10.21203/rs.3.rs-400230/v1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
66 Schijns V, Majhen D, van der Ley P, Thakur A, Summerfield A, Berisio R, Nativi C, Fernández-Tejada A, Alvarez-Dominguez C, Gizurarson S, Zamyatina A, Molinaro A, Rosano C, Jakopin Ž, Gursel I, McClean S. Rational Vaccine Design in Times of Emerging Diseases: The Critical Choices of Immunological Correlates of Protection, Vaccine Antigen and Immunomodulation. Pharmaceutics 2021;13:501. [PMID: 33917629 DOI: 10.3390/pharmaceutics13040501] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
67 Winkler MS, Skirecki T, Brunkhorst FM, Cajander S, Cavaillon JM, Ferrer R, Flohé SB, García-Salido A, Giamarellos-Bourboulis EJ, Girardis M, Kox M, Lachmann G, Martin-Loeches I, Netea MG, Spinetti T, Schefold JC, Torres A, Uhle F, Venet F, Weis S, Scherag A, Rubio I, Osuchowski MF. Bridging animal and clinical research during SARS-CoV-2 pandemic: A new-old challenge. EBioMedicine 2021;66:103291. [PMID: 33813139 DOI: 10.1016/j.ebiom.2021.103291] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
68 Liu R, Americo JL, Cotter CA, Earl PL, Erez N, Peng C, Moss B. One or two injections of MVA-vectored vaccine shields hACE2 transgenic mice from SARS-CoV-2 upper and lower respiratory tract infection. Proc Natl Acad Sci U S A 2021;118:e2026785118. [PMID: 33688035 DOI: 10.1073/pnas.2026785118] [Cited by in Crossref: 8] [Cited by in F6Publishing: 28] [Article Influence: 8.0] [Reference Citation Analysis]
69 Cho H, Jang Y, Park KH, Choi H, Nowakowska A, Lee HJ, Kim M, Kang MH, Kim JH, Shin HY, Oh YK, Kim YB. Human endogenous retrovirus-enveloped baculoviral DNA vaccines against MERS-CoV and SARS-CoV2. NPJ Vaccines 2021;6:37. [PMID: 33741992 DOI: 10.1038/s41541-021-00303-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
70 Case JB, Winkler ES, Errico JM, Diamond MS. On the road to ending the COVID-19 pandemic: Are we there yet? Virology 2021;557:70-85. [PMID: 33676349 DOI: 10.1016/j.virol.2021.02.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
71 Piepenbrink MS, Park JG, Oladunni FS, Deshpande A, Basu M, Sarkar S, Loos A, Woo J, Lovalenti P, Sloan D, Ye C, Chiem K, Bates CW, Burch RE, Erdmann NB, Goepfert PA, Truong VL, Walter MR, Martinez-Sobrido L, Kobie JJ. Therapeutic activity of an inhaled potent SARS-CoV-2 neutralizing human monoclonal antibody in hamsters. Cell Rep Med 2021;2:100218. [PMID: 33649747 DOI: 10.1016/j.xcrm.2021.100218] [Cited by in Crossref: 8] [Cited by in F6Publishing: 23] [Article Influence: 8.0] [Reference Citation Analysis]
72 Lundstrom K. Viral Vectors for COVID-19 Vaccine Development. Viruses 2021;13:317. [PMID: 33669550 DOI: 10.3390/v13020317] [Cited by in Crossref: 10] [Cited by in F6Publishing: 22] [Article Influence: 10.0] [Reference Citation Analysis]
73 Batty CJ, Heise MT, Bachelder EM, Ainslie KM. Vaccine formulations in clinical development for the prevention of severe acute respiratory syndrome coronavirus 2 infection. Adv Drug Deliv Rev 2021;169:168-89. [PMID: 33316346 DOI: 10.1016/j.addr.2020.12.006] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 37.0] [Reference Citation Analysis]
74 Brocato RL, Kwilas SA, Kim RK, Zeng X, Principe LM, Smith JM, Hooper JW. Protective efficacy of a SARS-CoV-2 DNA vaccine in wild-type and immunosuppressed Syrian hamsters. NPJ Vaccines 2021;6:16. [PMID: 33495468 DOI: 10.1038/s41541-020-00279-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 25] [Article Influence: 10.0] [Reference Citation Analysis]
75 Yang Y, Shi W, Abiona OM, Nazzari A, Olia AS, Ou L, Phung E, Stephens T, Tsybovsky Y, Verardi R, Wang S, Werner A, Yap C, Ambrozak D, Bylund T, Liu T, Nguyen R, Wang L, Zhang B, Zhou T, Chuang GY, Graham BS, Mascola JR, Corbett KS, Kwong PD. Newcastle Disease Virus-Like Particles Displaying Prefusion-Stabilized SARS-CoV-2 Spikes Elicit Potent Neutralizing Responses. Vaccines (Basel) 2021;9:73. [PMID: 33494381 DOI: 10.3390/vaccines9020073] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 13.0] [Reference Citation Analysis]
76 Furuyama W, Shifflett K, Pinski AN, Griffin AJ, Feldmann F, Okumura A, Gourdine T, Jankeel A, Lovaglio J, Hanley PW, Thomas T, Clancy CS, Messaoudi I, O'Donnell KL, Marzi A. Rapid protection from COVID-19 in nonhuman primates vaccinated intramuscularly but not intranasally with a single dose of a recombinant vaccine. bioRxiv 2021:2021. [PMID: 33501447 DOI: 10.1101/2021.01.19.426885] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 7.0] [Reference Citation Analysis]
77 Gould JR, Qiu S, Shang Q, Dokland T, Ogino T, Petit CM, Green TJ. Consequences of Phosphorylation in a Mononegavirales Polymerase-Cofactor System. J Virol 2021:JVI. [PMID: 33441337 DOI: 10.1128/JVI.02180-20] [Reference Citation Analysis]
78 Sauer MM, Tortorici MA, Park YJ, Walls AC, Homad L, Acton O, Bowen J, Wang C, Xiong X, de van der Schueren W, Quispe J, Hoffstrom BG, Bosch BJ, McGuire AT, Veesler D. Structural basis for broad coronavirus neutralization. bioRxiv 2021:2020. [PMID: 33398277 DOI: 10.1101/2020.12.29.424482] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 12.0] [Reference Citation Analysis]
79 Liu R, Americo JL, Cotter CA, Earl PL, Erez N, Peng C, Moss B. MVA Vector Vaccines Inhibit SARS CoV-2 Replication in Upper and Lower Respiratory Tracts of Transgenic Mice and Prevent Lethal Disease. bioRxiv 2021:2020. [PMID: 33442693 DOI: 10.1101/2020.12.30.424878] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
80 Yahalom-Ronen Y, Tamir H, Melamed S, Politi B, Shifman O, Achdout H, Vitner EB, Israeli O, Milrot E, Stein D, Cohen-Gihon I, Lazar S, Gutman H, Glinert I, Cherry L, Vagima Y, Lazar S, Weiss S, Ben-Shmuel A, Avraham R, Puni R, Lupu E, Bar-David E, Sittner A, Erez N, Zichel R, Mamroud E, Mazor O, Levy H, Laskar O, Yitzhaki S, Shapira SC, Zvi A, Beth-Din A, Paran N, Israely T. A single dose of recombinant VSV-∆G-spike vaccine provides protection against SARS-CoV-2 challenge. Nat Commun 2020;11:6402. [PMID: 33328475 DOI: 10.1038/s41467-020-20228-7] [Cited by in Crossref: 42] [Cited by in F6Publishing: 101] [Article Influence: 21.0] [Reference Citation Analysis]
81 Garcia-Beltran WF, Lam EC, Astudillo MG, Yang D, Miller TE, Feldman J, Hauser BM, Caradonna TM, Clayton KL, Nitido AD, Murali MR, Alter G, Charles RC, Dighe A, Branda JA, Lennerz JK, Lingwood D, Schmidt AG, Iafrate AJ, Balazs AB. COVID-19-neutralizing antibodies predict disease severity and survival. Cell 2021;184:476-488.e11. [PMID: 33412089 DOI: 10.1016/j.cell.2020.12.015] [Cited by in Crossref: 104] [Cited by in F6Publishing: 249] [Article Influence: 52.0] [Reference Citation Analysis]
82 Canedo-Marroquín G, Saavedra F, Andrade CA, Berrios RV, Rodríguez-Guilarte L, Opazo MC, Riedel CA, Kalergis AM. SARS-CoV-2: Immune Response Elicited by Infection and Development of Vaccines and Treatments. Front Immunol 2020;11:569760. [PMID: 33362758 DOI: 10.3389/fimmu.2020.569760] [Cited by in Crossref: 4] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
83 Farzani TA, Chov A, Herschhorn A. A protocol for displaying viral envelope glycoproteins on the surface of vesicular stomatitis viruses. STAR Protoc 2020;1:100209. [PMID: 33377103 DOI: 10.1016/j.xpro.2020.100209] [Reference Citation Analysis]
84 Ma X, Zou F, Yu F, Li R, Yuan Y, Zhang Y, Zhang X, Deng J, Chen T, Song Z, Qiao Y, Zhan Y, Liu J, Zhang J, Zhang X, Peng Z, Li Y, Lin Y, Liang L, Wang G, Chen Y, Chen Q, Pan T, He X, Zhang H. Nanoparticle Vaccines Based on the Receptor Binding Domain (RBD) and Heptad Repeat (HR) of SARS-CoV-2 Elicit Robust Protective Immune Responses. Immunity 2020;53:1315-1330.e9. [PMID: 33275896 DOI: 10.1016/j.immuni.2020.11.015] [Cited by in Crossref: 46] [Cited by in F6Publishing: 89] [Article Influence: 23.0] [Reference Citation Analysis]
85 Rathnasinghe R, Strohmeier S, Amanat F, Gillespie VL, Krammer F, García-Sastre A, Coughlan L, Schotsaert M, Uccellini MB. Comparison of transgenic and adenovirus hACE2 mouse models for SARS-CoV-2 infection. Emerg Microbes Infect 2020;9:2433-45. [PMID: 33073694 DOI: 10.1080/22221751.2020.1838955] [Cited by in Crossref: 40] [Cited by in F6Publishing: 70] [Article Influence: 20.0] [Reference Citation Analysis]
86 Lundstrom K. Application of Viral Vectors for Vaccine Development with a Special Emphasis on COVID-19. Viruses 2020;12:E1324. [PMID: 33218001 DOI: 10.3390/v12111324] [Cited by in Crossref: 8] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
87 Cimolai N. Applying Immune Instincts and Maternal Intelligence from Comparative Microbiology to COVID-19. SN Compr Clin Med 2020;:1-14. [PMID: 33195997 DOI: 10.1007/s42399-020-00634-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
88 Khoury DS, Wheatley AK, Ramuta MD, Reynaldi A, Cromer D, Subbarao K, O'Connor DH, Kent SJ, Davenport MP. Measuring immunity to SARS-CoV-2 infection: comparing assays and animal models. Nat Rev Immunol 2020;20:727-38. [PMID: 33139888 DOI: 10.1038/s41577-020-00471-1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 56] [Article Influence: 12.5] [Reference Citation Analysis]
89 Heinz FX, Stiasny K. Profile of SARS-CoV-2. Wien Klin Wochenschr 2020;132:635-44. [PMID: 33125580 DOI: 10.1007/s00508-020-01763-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
90 Scher G, Schnell MJ. Rhabdoviruses as vectors for vaccines and therapeutics. Curr Opin Virol 2020;44:169-82. [PMID: 33130500 DOI: 10.1016/j.coviro.2020.09.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
91 Garcia-Beltran WF, Lam EC, Astudillo MG, Yang D, Miller TE, Feldman J, Hauser BM, Caradonna TM, Clayton KL, Nitido AD, Murali MR, Alter G, Charles RC, Dighe A, Branda JA, Lennerz JK, Lingwood D, Schmidt AG, Iafrate AJ, Balazs AB. COVID-19 neutralizing antibodies predict disease severity and survival. medRxiv 2020:2020. [PMID: 33106822 DOI: 10.1101/2020.10.15.20213512] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
92 Wei J, Alfajaro MM, DeWeirdt PC, Hanna RE, Lu-Culligan WJ, Cai WL, Strine MS, Zhang SM, Graziano VR, Schmitz CO, Chen JS, Mankowski MC, Filler RB, Ravindra NG, Gasque V, de Miguel FJ, Patil A, Chen H, Oguntuyo KY, Abriola L, Surovtseva YV, Orchard RC, Lee B, Lindenbach BD, Politi K, van Dijk D, Kadoch C, Simon MD, Yan Q, Doench JG, Wilen CB. Genome-wide CRISPR Screens Reveal Host Factors Critical for SARS-CoV-2 Infection. Cell 2021;184:76-91.e13. [PMID: 33147444 DOI: 10.1016/j.cell.2020.10.028] [Cited by in Crossref: 105] [Cited by in F6Publishing: 192] [Article Influence: 52.5] [Reference Citation Analysis]
93 Seo SH, Jang Y. Cold-Adapted Live Attenuated SARS-Cov-2 Vaccine Completely Protects Human ACE2 Transgenic Mice from SARS-Cov-2 Infection. Vaccines (Basel) 2020;8:E584. [PMID: 33022950 DOI: 10.3390/vaccines8040584] [Cited by in Crossref: 12] [Cited by in F6Publishing: 26] [Article Influence: 6.0] [Reference Citation Analysis]
94 Krammer F. SARS-CoV-2 vaccines in development. Nature 2020;586:516-27. [DOI: 10.1038/s41586-020-2798-3] [Cited by in Crossref: 585] [Cited by in F6Publishing: 869] [Article Influence: 292.5] [Reference Citation Analysis]
95 Cimolai N. A Minimalist Strategy Towards Temporarily Defining Protection for COVID-19. SN Compr Clin Med 2020;:1-8. [PMID: 32984765 DOI: 10.1007/s42399-020-00533-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
96 Coughlan L. Snatching the Crown from SARS-CoV-2. Cell Host Microbe 2020;28:360-3. [PMID: 32910919 DOI: 10.1016/j.chom.2020.08.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
97 Bortz RH 3rd, Florez C, Laudermilch E, Wirchnianski AS, Lasso G, Malonis RJ, Georgiev GI, Vergnolle O, Herrera NG, Morano NC, Campbell ST, Orner EP, Mengotto A, Dieterle ME, Fels JM, Haslwanter D, Jangra RK, Celikgil A, Kimmel D, Lee JH, Mariano M, Antonio N, Jose Q, Rivera J, Szymczak WA, Tong K, Barnhill J, Forsell MNE, Ahlm C, Stein DT, Pirofski LA, Goldstein DY, Garforth SJ, Almo SC, Daily JP, Prystowsky MB, Faix JD, Fox AS, Weiss LM, Lai JR, Chandran K. Development, clinical translation, and utility of a COVID-19 antibody test with qualitative and quantitative readouts. medRxiv 2020:2020. [PMID: 32935116 DOI: 10.1101/2020.09.10.20192187] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
98 Callaway E. The underdog coronavirus vaccines that the world will need if front runners stumble. Nature 2020;585:332-3. [DOI: 10.1038/d41586-020-02583-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
99 Kumar V. Understanding the complexities of SARS-CoV2 infection and its immunology: A road to immune-based therapeutics. Int Immunopharmacol 2020;88:106980. [PMID: 33182073 DOI: 10.1016/j.intimp.2020.106980] [Cited by in Crossref: 11] [Cited by in F6Publishing: 18] [Article Influence: 5.5] [Reference Citation Analysis]
100 Jeyanathan M, Afkhami S, Smaill F, Miller MS, Lichty BD, Xing Z. Immunological considerations for COVID-19 vaccine strategies. Nat Rev Immunol. 2020;20:615-632. [PMID: 32887954 DOI: 10.1038/s41577-020-00434-6] [Cited by in Crossref: 280] [Cited by in F6Publishing: 411] [Article Influence: 140.0] [Reference Citation Analysis]
101 Melenotte C, Silvin A, Goubet AG, Lahmar I, Dubuisson A, Zumla A, Raoult D, Merad M, Gachot B, Hénon C, Solary E, Fontenay M, André F, Maeurer M, Ippolito G, Piacentini M, Wang FS, Ginhoux F, Marabelle A, Kroemer G, Derosa L, Zitvogel L. Immune responses during COVID-19 infection. Oncoimmunology 2020;9:1807836. [PMID: 32939324 DOI: 10.1080/2162402X.2020.1807836] [Cited by in Crossref: 24] [Cited by in F6Publishing: 56] [Article Influence: 12.0] [Reference Citation Analysis]